Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CHARIOT: a Phase 1b/2 Study of Androgen Deprivation Therapy and Copanlisib in High-Risk Localized Prostate Cancer Patients Prior to Radical Prostatectomy

Next Previous
Trial Profile

CHARIOT: a Phase 1b/2 Study of Androgen Deprivation Therapy and Copanlisib in High-Risk Localized Prostate Cancer Patients Prior to Radical Prostatectomy

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 04 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Copanlisib (Primary) ; Degarelix (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CHARIOT

Most Recent Events

  • 29 Oct 2024 According to ClinicalTrials.gov, this trial is Withdrawn as Study drug not available per sponsor
  • 29 Oct 2024 Status changed from active, no longer recruiting to discontinued.
  • 09 Oct 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top